Sidse Høst Pahus1, Anette Tarp Hansen1, Anne-Mette Hvas2. 1. Center for Hemophilia and Thrombosis, Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark. 2. Center for Hemophilia and Thrombosis, Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark. Electronic address: am.hvas@dadlnet.dk.
Abstract
INTRODUCTION: The possible significance of thrombophilia in ischemic stroke remains controversial. We aimed to study inherited and acquired thrombophilias as risk factors for ischemic stroke, transient ischemic attack (TIA) and amaurosis fugax in young patients. MATERIALS AND METHODS: We included patients aged 18 to 50 years with ischemic stroke, TIA or amaurosis fugax referred to thrombophilia investigation at Aarhus University Hospital, Denmark from 1 January 2004 to 31 December 2012 (N=685). Clinical information was obtained from the Danish Stroke Registry and medical records. Thrombophilia investigation results were obtained from the laboratory information system. Absolute thrombophilia prevalences and associated odds ratios (OR) with 95% confidence intervals (95% CI) were reported for ischemic stroke (N=377) and TIA or amaurosis fugax (N=308). Thrombophilia prevalences for the general population were obtained from published data. RESULTS: No strong associations were found between thrombophilia and ischemic stroke, but patients with persistent presence of lupus anticoagulant (3%) had an OR at 2.66 (95% CI 0.84-9.15) for ischemic stroke. A significantly higher risk of TIA/amaurosis fugax was found for factor V Leiden heterozygote (12%) (OR: 1.99 (95% CI 1.14-3.28)). No other inherited or acquired thrombophilia was associated with ischemic stroke, TIA or amaurosis fugax. CONCLUSIONS: In young patients, thrombophilia did not infer an increased risk of ischemic stroke. Only factor V Leiden heterozygote patients had an increased risk of TIA/amaurosis fugax, and persistent presence of lupus anticoagulant was likely associated with ischemic stroke. We suggest the testing restricted to investigation of persistent presence of lupus anticoagulant.
INTRODUCTION: The possible significance of thrombophilia in ischemic stroke remains controversial. We aimed to study inherited and acquired thrombophilias as risk factors for ischemic stroke, transient ischemic attack (TIA) and amaurosis fugax in young patients. MATERIALS AND METHODS: We included patients aged 18 to 50 years with ischemic stroke, TIA or amaurosis fugax referred to thrombophilia investigation at Aarhus University Hospital, Denmark from 1 January 2004 to 31 December 2012 (N=685). Clinical information was obtained from the Danish Stroke Registry and medical records. Thrombophilia investigation results were obtained from the laboratory information system. Absolute thrombophilia prevalences and associated odds ratios (OR) with 95% confidence intervals (95% CI) were reported for ischemic stroke (N=377) and TIA or amaurosis fugax (N=308). Thrombophilia prevalences for the general population were obtained from published data. RESULTS: No strong associations were found between thrombophilia and ischemic stroke, but patients with persistent presence of lupus anticoagulant (3%) had an OR at 2.66 (95% CI 0.84-9.15) for ischemic stroke. A significantly higher risk of TIA/amaurosis fugax was found for factor V Leiden heterozygote (12%) (OR: 1.99 (95% CI 1.14-3.28)). No other inherited or acquired thrombophilia was associated with ischemic stroke, TIA or amaurosis fugax. CONCLUSIONS: In young patients, thrombophilia did not infer an increased risk of ischemic stroke. Only factor V Leiden heterozygote patients had an increased risk of TIA/amaurosis fugax, and persistent presence of lupus anticoagulant was likely associated with ischemic stroke. We suggest the testing restricted to investigation of persistent presence of lupus anticoagulant.
Authors: Setareh S Omran; Michael P Lerario; Gino Gialdini; Alexander E Merkler; Antonio Moya; Monica L Chen; Hooman Kamel; Maria DeSancho; Babak B Navi Journal: J Stroke Cerebrovasc Dis Date: 2018-12-27 Impact factor: 2.136
Authors: Joanna Roskal-Wałek; Paweł Wałek; Michał Biskup; Jacek Sidło; Elżbieta Cieśla; Dominik Odrobina; Jerzy Mackiewicz; Beata Wożakowska-Kapłon Journal: J Clin Med Date: 2022-07-14 Impact factor: 4.964
Authors: Mijntje M I Schellekens; Mayte E van Alebeek; Renate M Arntz; Nathalie E Synhaeve; Noortje A M M Maaijwee; Hennie C Schoonderwaldt; Maureen J van der Vlugt; Ewoud J van Dijk; Loes C A Rutten-Jacobs; Frank-Erik de Leeuw Journal: J Thromb Thrombolysis Date: 2018-05 Impact factor: 2.300
Authors: Thita Chiasakul; Elizabeth De Jesus; Jiayi Tong; Yong Chen; Mark Crowther; David Garcia; Chatree Chai-Adisaksopha; Steven R Messé; Adam Cuker Journal: J Am Heart Assoc Date: 2019-09-24 Impact factor: 5.501